Jiangsu Hengrui Pharmaceuticals (600276.SH): The application for market approval for Insulin Injection (Shudiyindu) has been accepted.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has recently received a "Notice of Acceptance" from the National Medical Products Administration. The company's application for the market authorization of Category 1 therapeutic biological product Seglitide insulin injection has been accepted by the National Medical Products Administration. This product is the first domestically developed long-acting insulin analog. Seglitide insulin injection is a basic long-acting insulin independently developed by the company, with advantages such as smooth onset of action, long duration of action, and lower risk of nighttime hypoglycemia.